TrialDiabetes, obesity & metabolism2017

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.

Lawrence A Leiter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.